Affiliation:
1. Department of Sciences for Health Promotion and Mother and Child Care “G. D'Alessandro,” University of Palermo, Palermo, Italy
2. Pfizer Inc., Collegeville, Pennsylvania, USA
Abstract
Multidrug resistance among bacterial pathogens is an ongoing global problem and renders antimicrobial agents ineffective at treating bacterial infections. In the health care setting, infections caused by multidrug-resistant (MDR) Gram-negative bacteria can cause increased mortality, longer hospital stays, and higher treatments costs. The aim of the Tigecycline Evaluation and Surveillance Trial (TEST) is to assess the
in vitro
antimicrobial activities of tigecycline and other contemporary agents against clinically relevant pathogens. This paper presents antimicrobial activity data from the TEST study between 2004 and 2014 and examines global rates of MDR Gram-negative isolates, including
Acinetobacter baumannii
,
Pseudomonas aeruginosa
, and members of the
Enterobacteriaceae
, during this time. Our results show that tigecycline retained
in vitro
activity against many MDR Gram-negative pathogens over the study period, while rates of MDR
A. baumannii
increased globally. Using these findings, we hope to highlight the current status of multidrug resistance in medical facilities worldwide.
Publisher
American Society for Microbiology
Subject
Molecular Biology,Microbiology
Cited by
107 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献